Doug Cooper raises target to 19.75 $cdn sleep products.
“We believe VMD can help bring its expertise to grow its NIV business. While sleep should keep growing, VMD’s goal would be to grow NIV to 15-20 per cent of total revenue, which would imply NIV growth of ~35-40 per cent,” Cooper said.
The analyst is now calling for Viemed to deliver 2023 and 2024 revenue of $186.2 million and $225.1 million, respectively, and 2023 and 2024 EBITDA of $45.6 million and $57.0 million, respectively. (All figures in US dollars except where noted otherwise.)
Cooper has maintained a “Buy” rating and raised his target on VMD from C$18.00 to C$19.75, representing at press time a one-year projected return of 35 per cent